Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. OBJECTIVE: To evaluate the effect of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA
Päätekijät: Rosenstock, Julio, Perkovic, Vlado, Johansen, Odd Erik, Cooper, Mark E., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Pencina, Michael, Toto, Robert D., Wanner, Christoph, Zinman, Bernard, Woerle, Hans Juergen, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2018
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583576/
https://ncbi.nlm.nih.gov/pubmed/30418475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.18269
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia